Editorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia-Authors' Reply.
作者信息
Amangurbanova Maral, Loomba Rohit
机构信息
Division of Gastroenterology, MASLD Research Center, University of California at San Diego, San Diego, California, USA.
Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, San Diego, California, USA.
出版信息
Aliment Pharmacol Ther. 2025 Feb;61(4):729-730. doi: 10.1111/apt.18470. Epub 2024 Dec 30.
Abstract
摘要
相似文献
1
Editorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia-Authors' Reply.
Aliment Pharmacol Ther. 2025 Feb;61(4):729-730. doi: 10.1111/apt.18470. Epub 2024 Dec 30.
2
The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.糖尿病患者与非糖尿病患者以及代谢功能障碍相关脂肪性肝病患者中晚期肝纤维化的患病率及其相关因素：一项横断面研究。
J Diabetes Complications. 2025 Aug 6;39(10):109147. doi: 10.1016/j.jdiacomp.2025.109147.
4
Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.内脏脂肪与糖尿病：在代谢功能障碍相关脂肪性肝病中与肝纤维化的关联
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102378. doi: 10.1016/j.jceh.2024.102378. Epub 2024 Jul 19.
5
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.代谢功能障碍相关脂肪性肝病：肌肉与体重的故事。
World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346.
6
Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care.评估基层医疗中2型糖尿病患者代谢功能障碍相关脂肪性肝病的患病率和严重程度。
J Intern Med. 2025 Jun 16. doi: 10.1111/joim.20103.
7
[Metabolic dysfunction-associated steatotic liver disease in patients with prediabetes and type 2 diabetes mellitus].[糖尿病前期和2型糖尿病患者的代谢功能障碍相关脂肪性肝病]
Ter Arkh. 2025 Aug 28;97(8):689-695. doi: 10.26442/00403660.2025.08.203339.
8
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.社区中具有代谢和酒精风险个体的脂肪性肝病患病率、严重程度及决定因素
J Hepatol. 2025 Jul 4. doi: 10.1016/j.jhep.2025.06.020.
9
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.
Clin Gastroenterol Hepatol. 2025 Jul 2. doi: 10.1016/j.cgh.2025.06.014.
10
Higher Pre-Operative Non-Invasive Fibrosis Scores are not Associated with Surgical Outcomes in Patients with MASLD Undergoing Metabolic and Bariatric Surgery.较高的术前无创纤维化评分与接受代谢和减重手术的代谢相关脂肪性肝病（MASLD）患者的手术结局无关。
Can Liver J. 2025 Feb 12;8(2):284-289. doi: 10.3138/canlivj-2024-0015. eCollection 2025 May.
本文引用的文献
1
Editorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinemia.
Aliment Pharmacol Ther. 2025 Feb;61(4):727-728. doi: 10.1111/apt.18453. Epub 2024 Dec 30.
2
A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia.2型糖尿病合并高铁蛋白血症患者中代谢相关脂肪性肝病患病率的前瞻性研究
Aliment Pharmacol Ther. 2025 Feb;61(3):456-464. doi: 10.1111/apt.18377. Epub 2024 Nov 5.
3
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.血清铁蛋白水平可预测代谢功能障碍相关脂肪性肝病患者的长期预后。
Gut. 2024 Apr 5;73(5):825-834. doi: 10.1136/gutjnl-2023-330815.
4
A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia.基于人群的和临床队列验证新型代谢性高血铁定义的共识。
J Clin Endocrinol Metab. 2024 May 17;109(6):1540-1549. doi: 10.1210/clinem/dgad749.
5
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
6
Hyperferritinemia-A Clinical Overview.高铁蛋白血症——临床概述
J Clin Med. 2021 May 7;10(9):2008. doi: 10.3390/jcm10092008.
7
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.全球 2 型糖尿病患者非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学：系统评价和荟萃分析。
J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4.
Zotero 插件